FLP Wealth Management’s Novavax NVAX Stock Holding History

FLP Wealth Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-36	Closed	-$289	–	326
2024 Q4	$289	Buy	+36	New	+$347	﹤0.01%	437

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FLP Wealth Management's NVAX Position: Q1 2025 in Review

FLP Wealth Management sold out of Novavax (NVAX) in Q1 2025, closing a stake of 36 shares — an estimated $289 sold.

FLP Wealth Management first reported a position in NVAX in Q4 2024 and held it in 1 quarter. The position peaked at $289 in Q4 2024. 245 funds tracked by Wall St. Rank hold NVAX as of Q1 2025.

FLP Wealth Management reported no remaining Novavax position as of Q1 2025 after selling out during the quarter.
FLP Wealth Management sold 36 Novavax shares in Q1 2025, an estimated $289.
FLP Wealth Management first reported a position in Novavax in Q4 2024 and held it in 1 quarter.
FLP Wealth Management's Novavax position peaked at $289 in Q4 2024.
245 funds tracked by Wall St. Rank held Novavax as of Q1 2025.

Based on FLP Wealth Management's 13F filing for Q1 2025, filed 15 Jul 2025.